SCOTROC 2B: Feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer

A. R. Clamp, J. Mäenpää, D. Cruickshank, J. Ledermann, P. M. Wilkinson, R. Welch, S. Chan, P. Vasey, B. Sorbe, A. Hindley, G. C. Jayson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m-2 (arm A, n = 51) or docetaxel 60 mg m-2 with irinotecan 200 mg m-2 (arm B, n = 49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-8 1%; P = 0.079; arm B 67% (90% CI 55-78%; P = 0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-l inhibitors in this setting may be warranted. © 2006 Cancer Research.
    Original languageEnglish
    Pages (from-to)55-61
    Number of pages6
    JournalBritish Journal of Cancer
    Volume94
    Issue number1
    DOIs
    Publication statusPublished - 16 Jan 2006

    Keywords

    • Cancer
    • Carboplatin
    • Docetaxel
    • Irinotecan
    • Ovarian
    • Taxane

    Fingerprint

    Dive into the research topics of 'SCOTROC 2B: Feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer'. Together they form a unique fingerprint.

    Cite this